Slide 1: Clene
> cLene NASDAQ: CLNN: clene.com
Slide 2: EAP Participant Enrollment
EAP Participant Enrollment * AILEAP participants (CNM-Au8 30mg) enrolled through 15-December-2023 with EDC data entry * Survival updated through the 14-lanuary-2024 data cut {EAPOL in collaboration withthe: EAPOL EAPO2 (MGH) Healey Center (US, 16 sites) The Healey center covered ‘management through
Slide 3: EAP Baseline Demographics | At Study Entry
EAP Baseline Demographics | At Study Entry 5851122) 61.(1039) 59.3(116) 27,78) (22,84) (22,84) 205(39.4) 5421321) 49.7(952) Months from Symptom Onset, (n=256) 157,244 (65,2344 (57,244) 5 aesi2as) | 2070232) 19.4037) Diagnostic Delay (Months), 0-258) jos) | Tossa! (os) . casa) 57.6(249) 60.4254) Vita
Slide 4: Propensity Matched ALS Controls | Sources
Propensity Matched ALS Controls | Sources PRO-ACT ALS Natural History Study “The PRO-ACT database Delp Hd npn apt pm clens
Slide 5: Survival Analyses | Methodology
Survival Analyses | Methodology * Utilize longitudinal data from historical ALS controls: ALS Natural PRO-ACT soa a * Propensity matching based on baseline covariates (nominal caliper: 0.4) * Observation time as an additional matching covariate for sensitivity analyses << ————————— pm clens ‘Matchin
Slide 6: Survival Analyses | All-Cause Mortality
Survival Analyses | All-Cause Mortality * Log-rank (unadjusted) of all EAP (n=256) vs. propensity matched controls (n=220) * Covariate adjusted hazard ratio (EAP treatment vs. controls) ‘© EAP participants with baseline covariates (n=220) vs. propensity matched (n=220) ‘© Baseline Covariates: Onset
Slide 7: EAP Participants vs. Propensity Matched Controls
EAP Participants vs. Propensity Matched Controls @pAts. ALS Natural History Study Onset Age Months Pest-Onsot
Slide 8: EAP Survival vs. ALS Natural History Matched Controls
EAP Survival vs. ALS Natural History Matched Controls Control-Matched EAP and All EAP ALS Natural History Study | EAP Matched (n=220) ALS Natural History Study | All EAP (n=256) EAP Long-Term Survival EAP Long-Term Survival ‘ALS Natal toy Stat Propo Matcod Contos [ALS Natural Hesory Sy Propensity Ma
Slide 9: EAP Participants vs. Propensity Matched Controls
EAP Participants vs. Propensity Matched Controls @pAts. PRO-ACT ALSERS-R Score Dettafs Onset Age ‘Months Post Onset ital Capacity (%) ae cp a SERS ane ahh orem pm clens
Slide 10: EAP Survival vs. PRO-ACT Matched Controls
EAP Survival vs. PRO-ACT Matched Controls Control-Matched EAP and All EAP PRO-ACT | EAP Matched (n=220) PRO-ACT | All EAP (n=256) oe ee ont ea te bec no tse ce esd Poeun Baa os nz Sse Pecounsi x ator - aoereeenres i ie i i 5 757) | Cou Ae HI: 0.320 (95% CI: 0.178 -O575) i 75) cox HR 0.561 (958 CE 03
Slide 11: Survival | Sensitivity Analyses
Survival | Sensitivity Analyses pats Including Observation Time as an Additional Covariate for Propensity Score Matching ALS Natural History Study | EAP Matched PRO-ACT | EAP Matched Primary covariate model ozs | 0282-0663 Primary covariate model oxo | oa7e-os75 “Observation time for “Observation ti
Slide 12: Conclusions
Conclusions * Clene’s Expanded Access programs represent the longest continuous intermediate sized compassionate use program in ALS with over 256 participants treated © CNM-Au8 EAP longitudinal treatment duration exceeds 4 years of daily therapy * A significant survival benefit was observed from lon
Slide 13: Clene
> cLene y= ~=NANOMEDICINE